MHC class I-related chain B gene polymorphism is associated with virological response to pegylated interferon plus ribavirin therapy in patients with chronic hepatitis C infection.

about

MHC class I-related chain B gene polymorphism is associated with virological response to pegylated interferon plus ribavirin therapy in patients with chronic hepatitis C infection.

Item

http://www.wikidata.org/entity/Q41161023

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

MHC class I-related chain B ge ...... chronic hepatitis C infection.

@en

type

Item

label

MHC class I-related chain B ge ...... chronic hepatitis C infection.

@en

prefLabel

MHC class I-related chain B ge ...... chronic hepatitis C infection.

@en

P1476

MHC class I-related chain B ge ...... chronic hepatitis C infection.

@en

P2093

Akira Andoh

http://www.w3.org/2001/XMLSchema#string

Ayumi Asada

http://www.w3.org/2001/XMLSchema#string

Makoto Shioya

http://www.w3.org/2001/XMLSchema#string

Rie Osaki

http://www.w3.org/2001/XMLSchema#string

Takashi Nishimura

http://www.w3.org/2001/XMLSchema#string

Takayuki Takeuchi

http://www.w3.org/2001/XMLSchema#string

Yoshiaki Okumura

http://www.w3.org/2001/XMLSchema#string

P2860

Hepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia-Pacific region

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection

Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis.

Meta-analysis: mortality and serious adverse events of peginterferon plus ribavirin therapy for chronic hepatitis C.

Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study.

Efficacy and safety of pegylated interferon plus ribavirin therapy for chronic hepatitis C genotype 6: a meta-analysis

Inhibition of hepatocellular carcinoma by PegIFNα-2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study.

P304

247-253

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/BR.2014.406

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-12-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273961552

http://www.w3.org/2001/XMLSchema#string

P698

26075078

http://www.w3.org/2001/XMLSchema#string

P921

virology

P932

4448076

http://www.w3.org/2001/XMLSchema#string